PMID- 29552177
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 4
DP  - 2018 Apr
TI  - Improving immunotherapy for colorectal cancer using dendritic cells combined with 
      anti-programmed death-ligand in vitro.
PG  - 5345-5351
LID - 10.3892/ol.2018.7978 [doi]
AB  - Monoclonal antibodies recognizing programmed death-ligand 1 (PD-L1) have been 
      used for the clinical treatment of diverse tumor types as a form of immune 
      checkpoint inhibitor, with a favorable therapeutic effect. Dendritic cells (DCs) 
      are potent antigen-presenting cells that serve a pivotal role in the activation 
      of T cells, particularly cytotoxic T lymphocytes (CTLs). DC vaccines loaded with 
      tumor antigens, DC-CTLs and activated T cells have been revealed to be a safe and 
      effective treatment approach against colorectal cancer within a clinical setting. 
      In addition to tumor cells, PD-L1 is also highly expressed on DCs. As research 
      examining the association between anti-PD-L1 and DCs is lacking, the present 
      study compared the expression of PD-L1 on DCs in the peripheral blood of healthy 
      donors and patients with colorectal cancer. Following the application of 
      anti-PD-L1, the DC phenotypes, function of DC-mediated T cell induction and the 
      cytotoxicity of CTLs were investigated by flow cytometry. The present study 
      revealed that treatment with anti-PD-L1 may promote the maturation of DCs and 
      enhance the functionality of the DC1 subtype. It may also increase the number of 
      CTLs that are activated and produce CTL cells with more potent anti-tumor 
      activity. Therefore, the creation of DC vaccines in conjunction with anti-PD-L1 
      may be an effective future treatment strategy for patients with colorectal 
      cancer.
FAU - Hu, Zilong
AU  - Hu Z
AD  - Department of General Surgery, Chinese People's Liberation Army General Hospital, 
      Beijing 100853, P.R. China.
FAU - Ma, Yue
AU  - Ma Y
AD  - Department of General Surgery, Chinese People's Liberation Army General Hospital, 
      Beijing 100853, P.R. China.
FAU - Shang, Zhiyang
AU  - Shang Z
AD  - Department of Tumor Prevention and Rehabilitation, PKU Care Rehabilitation 
      Hospital, Beijing 102206, P.R. China.
FAU - Hu, Shidong
AU  - Hu S
AD  - Department of General Surgery, Chinese People's Liberation Army General Hospital, 
      Beijing 100853, P.R. China.
FAU - Liang, Kai
AU  - Liang K
AD  - Department of General Surgery, Chinese People's Liberation Army General Hospital, 
      Beijing 100853, P.R. China.
FAU - Liang, Wentao
AU  - Liang W
AD  - Department of General Surgery, Chinese People's Liberation Army General Hospital, 
      Beijing 100853, P.R. China.
FAU - Xing, Xiaowei
AU  - Xing X
AD  - Department of General Surgery, Chinese People's Liberation Army General Hospital, 
      Beijing 100853, P.R. China.
FAU - Wang, Yufeng
AU  - Wang Y
AD  - Department of Patient Admission Management, Chinese People's Liberation Army 
      General Hospital, Beijing 100853, P.R. China.
FAU - Du, Xiaohui
AU  - Du X
AD  - Department of General Surgery, Chinese People's Liberation Army General Hospital, 
      Beijing 100853, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180207
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5840640
OTO - NOTNLM
OT  - anti-programmed death-ligand 1
OT  - colorectal cancer
OT  - dendritic cells
OT  - immunotherapy
EDAT- 2018/03/20 06:00
MHDA- 2018/03/20 06:01
PMCR- 2018/02/07
CRDT- 2018/03/20 06:00
PHST- 2016/11/26 00:00 [received]
PHST- 2017/11/29 00:00 [accepted]
PHST- 2018/03/20 06:00 [entrez]
PHST- 2018/03/20 06:00 [pubmed]
PHST- 2018/03/20 06:01 [medline]
PHST- 2018/02/07 00:00 [pmc-release]
AID - OL-0-0-7978 [pii]
AID - 10.3892/ol.2018.7978 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Apr;15(4):5345-5351. doi: 10.3892/ol.2018.7978. Epub 2018 Feb 7.